These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 30610548)

  • 1. Bevacizumab and erlotinib versus bevacizumab for colorectal cancer treatment: systematic review and meta-analysis.
    Kaveh S; Ebrahimi P; Rezapour A; Mozafari M; Sayehmiri K
    Int J Clin Pharm; 2019 Feb; 41(1):30-41. PubMed ID: 30610548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival Benefit and Safety of Bevacizumab in Combination with Erlotinib as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: A Meta-Analysis.
    Xu W; Gong Y; Kuang M; Wu P; Cao C; Chen J; Tang C
    Clin Drug Investig; 2017 Feb; 37(2):155-165. PubMed ID: 27665469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial.
    Tournigand C; Chibaudel B; Samson B; Scheithauer W; Vernerey D; Mésange P; Lledo G; Viret F; Ramée JF; Tubiana-Mathieu N; Dauba J; Dupuis O; Rinaldi Y; Mabro M; Aucoin N; Latreille J; Bonnetain F; Louvet C; Larsen AK; André T; de Gramont A
    Lancet Oncol; 2015 Nov; 16(15):1493-1505. PubMed ID: 26474518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erlotinib in combination with bevacizumab has potential benefit in non-small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials.
    Zhao B; Zhang W; Yu D; Xu J; Wei Y
    Lung Cancer; 2018 Aug; 122():10-21. PubMed ID: 30032815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of erlotinib combined with bevacizumab in the treatment of non-small cell lung cancer: A systematic review and meta-analysis.
    Zhou K; Zhao S; Guo W; Ding L
    Medicine (Baltimore); 2020 Jan; 99(3):e18771. PubMed ID: 32011468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.
    Sun L; Ma JT; Zhang SL; Zou HW; Han CB
    Med Oncol; 2015 Feb; 32(2):473. PubMed ID: 25603953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis.
    Zhang S; Mao XD; Wang HT; Cai F; Xu J
    BMJ Open; 2016 Jun; 6(6):e011714. PubMed ID: 27363819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination strategies based on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for cancer patients: Pooled analysis and subgroup analysis of efficacy and safety.
    Xu R; Shao H; Zhu J; Ju Q; Shi H
    Medicine (Baltimore); 2019 Mar; 98(13):e14135. PubMed ID: 30921175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erlotinib plus bevacizumab versus erlotinib alone in patients with
    Deng W; Wang K; Jiang Y; Li D; Bao C; Luo J; Liu L; Huang B; Kong J
    BMJ Open; 2022 Aug; 12(8):e062036. PubMed ID: 35985780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis.
    Shui L; Wu YS; Lin H; Shui P; Sun Q; Chen X
    Cell Physiol Biochem; 2018; 48(5):1870-1881. PubMed ID: 30092572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab in combination with first-line chemotherapy in patients with metastatic colorectal cancer: a meta-analysis.
    Hu W; Xu WS; Liao XF; He HJ
    Minerva Chir; 2015 Dec; 70(6):451-8. PubMed ID: 26013763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial.
    Johnsson A; Hagman H; Frödin JE; Berglund A; Keldsen N; Fernebro E; Sundberg J; De Pont Christensen R; Garm Spindler KL; Bergström D; Jakobsen A
    Ann Oncol; 2013 Sep; 24(9):2335-41. PubMed ID: 23788755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer.
    Gridelli C; Rossi A; Ciardiello F; De Marinis F; Crinò L; Morabito A; Morgillo F; Montanino A; Daniele G; Piccirillo MC; Normanno N; Gallo C; Perrone F
    Clin Lung Cancer; 2016 Sep; 17(5):461-465. PubMed ID: 27209164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of bevacizumab combined with erlotinib for advanced hepatocellular carcinoma: a single-arm meta-analysis based on prospective studies.
    He L; Deng H; Lei J; Yi F; Li J; Fan X; Wei Y; Xu J; Zhang W
    BMC Cancer; 2019 Mar; 19(1):276. PubMed ID: 30922256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials.
    Wu YS; Shui L; Shen D; Chen X
    Oncotarget; 2017 Feb; 8(6):10703-10713. PubMed ID: 27793044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.
    Heinemann V; Rivera F; O'Neil BH; Stintzing S; Koukakis R; Terwey JH; Douillard JY
    Eur J Cancer; 2016 Nov; 67():11-20. PubMed ID: 27592068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis.
    Baraniskin A; Buchberger B; Pox C; Graeven U; Holch JW; Schmiegel W; Heinemann V
    Eur J Cancer; 2019 Jan; 106():37-44. PubMed ID: 30476731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Bevacizumab Combined With Fluoropyrimidine Monotherapy for Unfit or Older Patients With Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Pinto C; Antonuzzo L; Porcu L; Aprile G; Maiello E; Masi G; Petrelli F; Scartozzi M; Torri V; Barni S
    Clin Colorectal Cancer; 2017 Jun; 16(2):e61-e72. PubMed ID: 27687553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing Efficacy of Erlotinib and Bevacizumab Combination with Erlotinib Monotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis.
    Sakharkar P; Kurup S
    Diseases; 2023 Oct; 11(4):. PubMed ID: 37873790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous versus intermittent chemotherapy strategies in metastatic colorectal cancer: a systematic review and meta-analysis.
    Berry SR; Cosby R; Asmis T; Chan K; Hammad N; Krzyzanowska MK;
    Ann Oncol; 2015 Mar; 26(3):477-85. PubMed ID: 25057174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.